These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Lheureux S; Braunstein M; Oza AM CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893 [TBL] [Abstract][Full Text] [Related]
49. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Ashworth A; Lord CJ Nat Rev Clin Oncol; 2018 Sep; 15(9):564-576. PubMed ID: 29955114 [TBL] [Abstract][Full Text] [Related]
50. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Kurnit KC; Fleming GF; Lengyel E Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287 [TBL] [Abstract][Full Text] [Related]
52. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332 [TBL] [Abstract][Full Text] [Related]
53. The role of niraparib for the treatment of ovarian cancer. Ethier JL; Lheureux S; Oza AM Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239 [TBL] [Abstract][Full Text] [Related]
54. Management and Treatment of Recurrent Epithelial Ovarian Cancer. Armbruster S; Coleman RL; Rauh-Hain JA Hematol Oncol Clin North Am; 2018 Dec; 32(6):965-982. PubMed ID: 30390768 [TBL] [Abstract][Full Text] [Related]
55. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer. Lavie O; Chetrit A; Novikov I; Sadetzki S; Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026 [TBL] [Abstract][Full Text] [Related]
56. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. Senhaji Mouhri Z; Goodfellow E; Jean-Claude B BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752 [TBL] [Abstract][Full Text] [Related]
57. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Okuma HS; Yonemori K Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689 [TBL] [Abstract][Full Text] [Related]
58. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752 [TBL] [Abstract][Full Text] [Related]
59. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics. Rabenau K; Hofstatter E Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114 [TBL] [Abstract][Full Text] [Related]
60. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]